A Phase I Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination with L19-IL2 As a Treatment of Metastatic FAP-positive Solid Tumors
Latest Information Update: 28 Jan 2025
At a glance
- Drugs 177-Lu-OncoFAP-23 (Primary) ; Bifikafusp alfa (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Acronyms Theratri
- Sponsors Philogen
Most Recent Events
- 22 Jan 2025 Planned initiation date changed from 31 Dec 2024 to 31 May 2025.
- 14 Oct 2024 Status changed from planning to not yet recruiting.
- 04 Apr 2023 New trial record